scispace - formally typeset
A

Anders Karlén

Researcher at Uppsala University

Publications -  116
Citations -  4192

Anders Karlén is an academic researcher from Uppsala University. The author has contributed to research in topics: Protease & Angiotensin II. The author has an hindex of 33, co-authored 114 publications receiving 3525 citations.

Papers
More filters
Journal ArticleDOI

Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.

TL;DR: The effective permeability (Peff) in the human jejunum (in vivo) of 22 structurally diverse compounds was correlated with both experimentally determined lipophilicity values and calculated molecular descriptors, and models that correlate passive intestinal permeability to physicochemical descriptors were derived.
Journal ArticleDOI

The global preclinical antibacterial pipeline.

TL;DR: The innovative potential of the preclinical pipeline compared with the clinical pipeline is encouraging but fragile and much more work, focus and funding are needed for the novel approaches to result in effective antibacterial therapies to sustainably combat antibacterial resistance.
Journal ArticleDOI

Towards the sustainable discovery and development of new antibiotics

TL;DR: In this paper, the authors present a strategic blueprint to substantially improve our ability to discover and develop new antibiotics, and propose both short-term and long-term solutions to overcome the most urgent limitations in the various sectors of research and funding.
Journal ArticleDOI

Relationships between structure and interaction kinetics for HIV-1 protease inhibitors.

TL;DR: The interaction between HIV-1 protease and 58 structurally diverse transition-state analogue inhibitors has been analyzed by a surface plasmon resonance based biosensor and shows that different classes of inhibitors fall into distinct clusters in maps.
Journal ArticleDOI

Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor.

TL;DR: Two cyclic, C2-symmetric HIV-1 protease inhibitors, one sulfamide and one urea derivative, both comprising phenyl ether groups in the P1/P1' positions, were cocrystallized with HIV- 1 protease, and the crystal structures were determined to 2.0 A resolution.